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will suffer end-stage renal disease within the 
first 10 years.2,3  The presence of lupus nephritis 
significantly reduces survival to approximately 
88% at 10 years.2 Until now, lupus nephritis is still 
make a significant mortality and morbidity of SLE 
patients. Therefore, there is an urgent need for a 
lupus nephritis diagnostic marker. 
 Renal biopsy is the gold standard for lupus 
nephritis, however biopsy relatively expensive and 
need special equipment. Therefore, renal biopsy 
is not practical enough as a routine examination. 
The diagnostic criteria for lupus nephritis based 
on 1997 American College of Rheumatology 
(ACR) are 24 hours urine protein  ≥ 500 mg and 
or cellular/granular cast. However the criteria has 
limitations, that significant renal damage can occur 
without proteinuria or cast in the urine.4 Anti-C1q 
is an autoantibody that is produced by a chronic 
change of C1q collagen domain. Anti-C1q only 
produced when C1q is in its bound form, therefore 
the pathological role of anti-C1q is local, and 
specific for lupus nephritis.5,6 Several studies had 
been conducted to investigate anti-C1q, however 
the studies are controversial. Moura et al.7 in 2011 
found that anti-C1q serum has 86.66% sensitivity, 
74.4% specificity, 52% positive predictive value, 
94.59% negative predictive value for the diagnosis 
of lupus nephritis. Moura concluded that anti-C1q 
can be used as a lupus nephritis diagnostic marker 
therefore reduced renal biopsy. Meyer et al.8 in 2009 
found anti-C1q serum has 100% sensitivity, 95.7% 
specificity, 100% positive predictive value, 50% 
negative predictive value. In contrary, Katsumata et 
al.9 found that anti-C1q serum level was correlated 
with lupus global activity and not correlated with 
lupus nephritis. Heindenreich et al.10 also found 
anti-C1q validity was lower than anti-dsDNA in 
diagnosing lupus nephritis. This study aimed to 
determine the validity of anti-C1q serum using 
1997 American College of Rheumatology criteria 
for SLE as a gold standard. 
METHODS
Study design
This is an analytical-observational study with 
cross-sectional design. The study was performed at 
Rheumatology Clinics/Division of Rheumatology 
of the Department of Internal Medicine and Clinical 
Pathologic Department at Hasan Sadikin General 
ABSTRACT
Background: Lupus nephritis is defined as renal 
involvement in systemic lupus erythematosus (SLE) 
patients and the most important cause of morbidity 
and mortality. The diagnostic criteria that used to 
diagnose lupus nephritis are 1997 American College 
of Rheumatology is 24 hours urine protein ≥500 mg 
and/or cellular cast, but significant renal damage can 
occur without proteinuria or cellular cast. Anti-C1q is an 
autoantibody that is produced by a chronic alteration of 
C1q collagen domain. Anti-C1q is a new specific marker 
for renal marker. 
Objective: To determine the validity of anti-C1q serum 
by using 1997 American College of Rheumatology 
criteria as a gold standard. 
Methods: This is a cross sectional study, conducted 
in October to December 2014 at Hasan Sadikin 
Hospital Bandung. The subjects had systemic lupus 
erythematosus with and without renal involvement, 
based on 1997 American College of Rheumatology 
criteria for SLE. 
Results: There were 65 subjects included in this 
study, 64 subjects were female and 1 subject was 
male. The age average was 32 (SD 11.7) years old. 
As many as 66.2% subjects had been diagnosed 
with lupus erythematosus systemic at least 3 years. 
Twenty four hours urine protein was measured using 
spectrophotometry, urine sediment was examined 
for cellular cast, and anti-C1q serum was measured 
using micro enzyme linked immunosorbent assay. 
Based on American College of Rheumatology criteria, 
34 subjects were classified as lupus nephritis group 
while 31 subjects were classified as non-lupus nephritis 
group. The area under the curve of anti-C1q was 0.610. 
The cut-off value used in this study was 10.43 U/ml. 
The sensitivity, specificity, positive predictive value, 
negative predictive value and accuracy of anti-C1q assay 
were 41.18%, 77.42%, 66.67%, 54.55% and 58.46% 
respectively. 
Conclusion: Anti-C1q assay, based on this study, has 
a low sensitivity and medium specificity to detect lupus 
nephritis.
Kidney is the most common organ involvement 
on systemic lupus erythematosus (SLE).1 
Approximately 55% of SLE patients developing 
nephritis during the first 10 years of disease and 
approximately more than 25% of these patients 
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Hospital, Bandung from October 2014 until December 2014. 
This study has passed the ethical clearance set by the ethical 
committee.  
Subjects
The subjects of this study were patients that have been 
diagnosed as SLE with and without renal involvement based 
on ACR criteria and have been receiving immunosuppressant 
therapy, in Rheumatology Clinics at Hasan Sadikin General 
Hospital. The sample size was calculated using formula for 
diagnostic test. The minimal sample for this study was 65 
samples. All participants have given consent to be enrolled in 
this study.
 The inclusion criteria were SLE patients with and without 
renal involvement. The exclusion criteria were patients 
in their menstrual cycle; urinary tract infection; other 
glomerulopathies; inadequate 24-hours urine collection, serum 
with hemolysis, icteric or lipemia; icteric 24-hours urine. 
History taking was done in all patients to collect demographic 
characteristics and laboratory test according to the needs for 
data collection. 
 Blood, spot urine and 24-hours urine collection were 
performed to acquire necessary data. Serum was obtained 
from phlebotomy to measure anti-C1q. Serum was collected 
in the -20oC until the minimal sample acquired. Anti-C1q was 
assayed using indirect micro enzyme linked immunosorbent 
assay (Orgentec, Germany). The measurement scale is 
numeric.
 Spot urine was collected from the midstream urine. 
Routine urinalysis and sediment analysis was performed for 
all subjects. Total urine creatinine was done before protein 
urine examination to determine 24-hours urine adequacy. 
Inadequate 24-hours urine was determined as ratio (predicted 
creatinine- total urine creatinine)/ predicted creatinine > 0.2. 
The inadequate 24-hours urine was excluded if the second 
24-hours urine recollection was inadequate. Twenty-four 
hours urine protein determined by spectrophotometry.  
 The collection of the specimens was done at outpatient’s 
laboratory, Clinical Pathologist Department, Hasan Sadikin 
Hospital. Routine urine examination and total urine protein 
was examined at Chemical Division, Clinical Pathologist 
Department, Hasan Sadikin Hospital. Anti-C1q serum was 
examined at Immunoserology Division, Clinical Pathology 
Department, Hasan Sadikin Hospital. 
 The data collected were processed using Statistical Package 
for the Social Sciences (SPSS) program. Kolmogorov-
Smirnov test was used to describe the data distribution. 
Receiver operating characteristics was used to determined 
cut-off value and validity testing was used to determined 
sensitivity, specificity, positive predictive value, negative 
predictive value and accuracy. 
RESULTS
During the study timeline, informed consent was done to 
85 subjects. Fourteen subjects were excluded because of 
urinary tract infection and 4 subjects because of menstrual 
period. Inadequate 24-hours urine collection was found in 5 
subjects, therefore the collection was repeated. Three subjects 
eventually met the criteria, while 2 other subjects were not met 
the criteria. Sixty five subjects were classified into 2 groups, 
which were 34 subjects with lupus nephritis and 31 subjects 
without lupus nephritis. The age mean in lupus nephritis group 
was 31.23 years old, while in non-lupus nephritis group was 
34.43 years old. Characteristics of subjects are presented in 
Table 1.
Table 1 Characteristics of subjects
Variable 24-hours urine 
protein  ≥ 
500 mg and or 
cellular cast 
(n=34)
24-hours urine 
protein  < 500 
mg without 
cellular cast 
(n=31)
p
Age (years old) 0.274*)
Mean (SD) 31.23 (11.17) 34.43 (12.25)
Age at SLE 
diagnosed (years 
old)
Mean 27.31 28.73 0.582*)
SD 10.01 10.75
Gender
Male 1 (1.5%) 0 (0%) 0.538**)
Female 33 (50.8%) 31 (47.7%)
Duration of illness 
< 3 years 14 (21.5%) 8 (12.3%) 0.385**)
≥ 3 years 20 (30.8%) 23 (35.4%)
Chief complaints
Photosensitivity 2 (3%)
7 (11%)
11 (17%)
5 (8%)
5 (8%)
1 (1%)
34 (52%)
Malar rash
Lupus hair
Arthralgia
Fatigue
Ankle edema
Without complaint
*) Independent t-test   **) chi square test 
n= total subject, SD = standard deviation, p= probability
 Sensitivity and specificity value for various anti-C1q 
cut off value are presented in Table 2. Cut off value used in 
this study is 10.43 U/ml with 40% sensitivity and 76.6% 
specificity. 
Table 2 Sensitivity and specificity value 
for various anti-C1q cut off value
Anti-C1q cut-off 
value (U/ml)
Sensitivity (%) Specificity (%)
≥ 1.10 94.3 23
≥ 2.15 94.3 30
≥ 2.35 88.6 30
≥ 2.55 85.7 30
≥ 3.05 74.3 30
≥ 4.05 62.9 46.7
≥ 5.76 51.4 66.7
≥ 6.91 45.7 70
≥ 8.00 45.7 73.3
≥10.43
≥12.22
40
37
76.7
76.7
     Receiver operating characteristics curve for anti-C1q is 
presented in Figure 1. Area under the curve for anti-C1q was 
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0.610. Validity testing results for anti-C1q with cut off value 
10.43 U/ml were 41.18% sensitivity, 77.42% specificity, 
66.67% positive predictive value, 54.55% negative predictive 
value and 58.46% accuracy, is presented in Table 3.     
Figure 1 Receiver operating characteristics curve for anti-C1q
Table 3 Validity testing Anti-C1q in Lupus Nephritis
 Lupus Nephritis
Variable 24-hours urine 
protein  ≥ 
500 mg and or 
cellular cast 
(n=34)
24-hours urine 
protein  < 500 
mg without 
cellular cast 
(n=31)
Total 
Anti-C1q
Positive ≥ 10.43 U/ml 14 7  21
Negative<10.43 U/ml 20 24 44
Total 34 31 65
DISCUSSION
 It is already known that lupus nephritis has higher 
incidence and prevalence among Asian patients, with lower 
survival rate. Renal biopsy is a gold standard for diagnosing 
lupus nephritis but biopsy is relatively more expensive than 
conventional parameters (urine protein and cellular/granular 
cast). However, significant renal damage can take place 
without proteinuria or cast. Therefore this study was aimed to 
determine the validity of anti-C1q as the new marker for lupus 
nephritis. 
 The age average of the subjects was 32.71 years old 
with 27.99 years old as the age average at the time of SLE 
diagnosed. This age average does not differs from other 
studies, which stated that SLE can occur at any age, but the 
most common age is 10-50 years old. Approximately 85% 
SLE happens before 50 and 20% happens in less than 16 
years old. Younger SLE patients was correlated with worse 
prognosis and manifestation, especially renal manifestation.11 
 The female gender was more common gender in this 
study. Systemic lupus erythematosus was more common in 
female (83-97%) with 9:1 ratio. This ratio increased to 11:1 in 
reproductive age of the female. Although the exact etiology of 
SLE was not been determined, these fact causing a theory that 
hormonal factor acts as a risk factor for SLE. 4 
 Majority of the subjects (66.2%) have been diagnosed SLE 
for ≥ 3 years. Duration of illness was measured since lupus 
nephritis can develop in early and late onset of SLE. Lupus 
nephritis that occur during the early onset of SLE is one of the 
factor that determine worse prognosis of SLE.12  
 Photosensitivity, malar rash, lupus hair, is mucocutaneous 
manifestation of SLE, while arthralgia is musculoskeletal 
manifestation.13,14 Fatigue can happen in 50-90% SLE patients 
and can be related to depression or pain.15 Edema is one of 
renal manifestation, found in one subject which has proteinuria 
> 3500 mg/24 hours.12
Validity of anti-C1q Serum     
Cut off used in this study is 10.43 U/ml since this value 
produced highest specificity, in line with the aim of this study. 
Cut-off 2.15 U/ml produced highest sensitivity but it cannot be 
used as cut off value since this value can be found in normal 
population (range 0.9 – 4.2 U/ml).16 
 The result of this study is different from Moura or Meyer 
study that showed a good sensitivity and specificity of anti-
C1q serum. This study only showed moderate specificity 
(77.42%) and poor sensitivity (41.18%). Several factors may 
contribute to this discrepancy. 
 Twenty out of 34 subjects produced false negative value. 
False negative value will affect sensitivity value. False 
negative value can be explained by several factors, such as 
immunosuppressant and/or chemotherapy that have been 
given to the subjects. Immunosuppressant therapy is drugs 
that suppress immune response so it can alter anti-C1q serum 
level. Chemotherapy is an alkylating agent that induced cell 
death includes B cell. B cell reduction will also reduce anti-
C1q serum level. 
 In some subjects, lupus nephritis was determined only by 
granular cast. Some subjects have urine protein range from 
510.4-690 mg/dl. Urine protein level and urinary cast are used 
to determine the severity of lupus nephritis. Cai et al.17 stated 
that anti-C1q serum level positively correlated with renal 
damage level and there were significant difference between 
classes II, III and IV lupus nephritis. These subjects can be 
classified as class I or class II, with minimal renal damage, so 
that anti-C1q level possibly still low. 
 Other factor that may contribute to false negative results 
is anti-C1q binding as immune complexes in glomerulus. 
Mannik et al.18 found that anti-C1q/IgG ratio in glomerulus 
was 50 times higher than anti-C1q/IgG ratio in serum, 
therefore causing a lower level of anti-C1q in serum. 
     Proteinuria was used as gold standard in this study, however 
proteinuria has several limitations. Persistent proteinuria not 
always correlated with renal inflammation but can occur in 
urinary tract infection or other glomerulopathy. This condition 
had been excluded in this study. 
 Seven out of 31 subjects produced false positive results. 
False positive value will affect specificity value. These can 
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be explained by several factors. Proteinuria and/or cast were 
used as the gold standard in this study. Stine and Arenas stated 
a condition called silent lupus nephritis, condition, which 
significant renal damage occurs without proteinuria and or 
urinary cast.19,20 Stine found 4 out of 16 subjects were classified 
as class III and IV lupus nephritis by renal biopsy, but these 
subjects had normal creatinine and slightly increase urine 
protein. Other possibility of false positive result is increased 
disease activity in other organs. Katsumata et al.9 stated that 
anti-C1q serum was correlated with global lupus activity and 
not specifically correlated with active lupus nephritis. 
     The result of this study is different from other studies that 
produce a good validity of anti-C1q serum. The limitation 
of this study is using SLE patients that have been receiving 
therapy. 
CONCLUSION
     Based on this study, anti-C1q assay has a low sensitivity 
and moderate specificity to detect lupus nephritis, therefore 
anti-C1q serum cannot be used solely to detect lupus nephritis. 
The actual validity of anti-C1q serum to detect lupus nephritis 
is still to be proven in further studies.
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